Nkarta (NKTX) Competitors $1.97 -0.10 (-4.83%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.57%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. MRVI, ORGO, KROS, TERN, MGTX, PVLA, ANAB, ORKA, XNCR, and SIGAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Maravai LifeSciences (MRVI), Organogenesis (ORGO), Keros Therapeutics (KROS), Terns Pharmaceuticals (TERN), MeiraGTx (MGTX), Palvella Therapeutics (PVLA), AnaptysBio (ANAB), Oruka Therapeutics (ORKA), Xencor (XNCR), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Maravai LifeSciences Organogenesis Keros Therapeutics Terns Pharmaceuticals MeiraGTx Palvella Therapeutics AnaptysBio Oruka Therapeutics Xencor Siga Technologies Maravai LifeSciences (NASDAQ:MRVI) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk. Does the media favor MRVI or NKTX? In the previous week, Maravai LifeSciences had 5 more articles in the media than Nkarta. MarketBeat recorded 8 mentions for Maravai LifeSciences and 3 mentions for Nkarta. Nkarta's average media sentiment score of 1.75 beat Maravai LifeSciences' score of 1.34 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in MRVI or NKTX? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by company insiders. Comparatively, 8.4% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, MRVI or NKTX? Nkarta has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$259.18M2.63-$144.85M-$1.36-1.96NkartaN/AN/A-$108.79M-$1.48-1.33 Is MRVI or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-90.03% -17.60% -9.30% Nkarta N/A -27.74%-22.38% Which has more volatility and risk, MRVI or NKTX? Maravai LifeSciences has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Do analysts rate MRVI or NKTX? Maravai LifeSciences currently has a consensus target price of $5.22, indicating a potential upside of 95.46%. Nkarta has a consensus target price of $13.60, indicating a potential upside of 590.36%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryNkarta beats Maravai LifeSciences on 11 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.02M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-1.3321.1774.5225.93Price / SalesN/A472.61547.62126.81Price / CashN/A46.6837.5660.44Price / Book0.349.6112.166.29Net Income-$108.79M-$53.29M$3.28B$270.77M7 Day Performance-12.83%0.28%0.87%3.88%1 Month Performance-10.86%5.73%4.96%4.88%1 Year Performance-65.50%10.52%60.75%26.01% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.3331 of 5 stars$1.97-4.8%$13.60+590.4%-64.8%$147.02MN/A-1.33140Positive NewsMRVIMaravai LifeSciences3.5493 of 5 stars$2.44-2.8%$5.22+113.9%-69.0%$640.96M$259.18M-1.79610Positive NewsGap UpORGOOrganogenesis3.9978 of 5 stars$4.77-4.6%$7.50+57.2%+88.9%$634.29M$482.04M-34.07950Positive NewsHigh Trading VolumeKROSKeros Therapeutics3.4599 of 5 stars$15.47-0.8%$30.00+93.9%-72.2%$633.19M$3.55M49.90100Positive NewsTERNTerns Pharmaceuticals4.0063 of 5 stars$7.28+0.8%$15.61+114.4%-24.0%$631.83MN/A-7.0040Positive NewsMGTXMeiraGTx4.1861 of 5 stars$7.47-2.9%$24.00+221.3%+82.5%$618.64M$33.28M-3.66300Positive NewsPVLAPalvella Therapeutics1.8861 of 5 stars$55.02-1.2%$58.50+6.3%N/A$615.80M$42.81M-4.55N/AAnalyst ForecastANABAnaptysBio2.4526 of 5 stars$22.19+1.3%$46.13+107.9%-38.9%$613.13M$91.28M-4.95100Positive NewsORKAOruka Therapeutics2.2613 of 5 stars$15.80-3.4%$40.38+155.5%-40.8%$612.32MN/A-5.62N/APositive NewsXNCRXencor3.9069 of 5 stars$8.41-1.6%$22.25+164.6%-58.7%$609.81M$110.49M-3.50280SIGASiga Technologies1.6195 of 5 stars$8.66+2.9%N/A+13.3%$602.92M$138.72M7.6640Positive News Related Companies and Tools Related Companies Maravai LifeSciences Competitors Organogenesis Competitors Keros Therapeutics Competitors Terns Pharmaceuticals Competitors MeiraGTx Competitors Palvella Therapeutics Competitors AnaptysBio Competitors Oruka Therapeutics Competitors Xencor Competitors Siga Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
